Universiti Kebangsaan Malaysia Research Ethics Committee has been reinstated and is now registered with the Drug Control Authority under the National Pharmaceutical Control Bureau. The HUKM Research Ethics Committee is now able to accept submissions for ethics approval.
Yisheng Biopharma Co., Ltd. (Yisheng Biopharma), a biopharmaceutical company, announced that a new vaccine for the post exposure treatment of the rabies infection was entering human clinical trial after a six-year long collaboration with a number of research institutes worldwide.
This project was named a “National Key Medicine Innovation” in 2013 and funded by the National Ministry of Science and Technology of China. This medical breakthrough was evaluated and endorsed by 30 scientists and experts on virology, immunology, clinic and biopharmaceuticals at the Rabies Infection and PIKA Rabies Vaccine Conference held in Beijing on March 8, 2015. This new vaccine product is currently under phase I clinical study in Singapore.
Do you have any queries?